UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): July 28, 2016

 

 

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

 

 

Indiana   0-23357   35-1345024
(State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

 

2701 KENT AVENUE

WEST LAFAYETTE, INDIANA

 

 

47906-1382

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (765) 463-4527

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 Item 7.01 Regulation FD Disclosure

 

On July 28, 2016, the Company’s Board of Directors voted unanimously to elect Larry S. Boulet as Chairman of the Board. Mr. Boulet has served as a director and Chairman of the Audit Committee of the Company since 2007. The knowledge that Mr. Boulet has gained from his tenure on the Company’s Board of Directors will be a valuable asset in helping to build and lead the Company’s strategy for growth. Mr. Boulet also provides our Board of Directors with insight and perspective on accounting and financial matters, stemming from his extensive experience as an audit partner.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOANALYTICAL SYSTEMS, INC.  
     
     
Date: August 4, 2016 By:  /s/ Jill C. Blumhoff  
    Jill C. Blumhoff
Chief Financial Officer,
Vice President of Finance